CB1 receptor mediation of cannabinoid behavioral effects in male and female rats

被引:35
作者
Tseng, AH
Craft, RM [1 ]
机构
[1] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA
[2] Washington State Univ, Coll Pharm, Program Pharmacol & Toxicol, Pullman, WA 99164 USA
关键词
sex differences; analgesia; catalepsy; cannabinoid; SR141716A; delta-9-tetrahydrocannabinol;
D O I
10.1007/s00213-003-1620-x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale. Cannabinoids have been shown to produce greater behavioral effects in female than male rats. Although central nervous system CB1 receptors are known to mediate cannabinoid-induced behavioral effects in male rats, it is not known whether the same is true for females. Objective. To determine if cannabinoid-induced antinociception and catalepsy are similarly mediated by central CB1 receptors in male and female rats. Methods. The ability of SR141716A, a CB1 receptor selective antagonist, administered ICV (1-1000 mug) or IT (1-600 mug) to block 10 mg/kg IP Delta(9)-THC-induced antinociception (paw pressure) and catalepsy (bar test), was compared in male and female rats. Results. Delta(9)-THC alone produced slightly greater antinociception, and significantly greater catalepsy in females than males. When administered ICV, SR141716A partially antagonized Delta(9)-THC-induced antinociception in both females and males. IT SR141716A also antagonized Delta(9)-THC-induced antinociception in both sexes; it was slightly more potent in males but equally effective in males and females. SR141716A antagonized Delta(9)-THC-induced catalepsy in a similar manner in males and females when given ICV or IT. Conclusions. These results confirm that Delta(9)-THC-induced behavioral effects are mediated by central CB1 receptors in male and female rats.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 21 条
[1]  
BORGEN LA, 1973, RES COMMUN CHEM PATH, V5, P621
[2]  
Cohn RA, 1972, DRUG ADDICTION EXPT, V1, P227
[3]  
DEFONSECA FAR, 1993, LIFE SCI, V54, P159
[4]  
FREEMAN ME, 1998, PHYSL REPROD, P1893
[5]   Sex steroid influence on cannabinoid CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland [J].
González, S ;
Bisogno, T ;
Wenger, T ;
Manzanares, J ;
Milone, A ;
Berrendero, F ;
Di Marzo, V ;
Ramos, JA ;
Fernández-Ruiz, JJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 270 (01) :260-266
[6]  
KENAKIN TP, 1984, PHARMACOL REV, V36, P165
[7]   The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats [J].
Lichtman, AH ;
Martin, BR .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 57 (1-2) :7-12
[8]  
LICHTMAN AH, 1991, J PHARMACOL EXP THER, V258, P517
[9]   ANTINOCICEPTIVE ACTIONS OF CANNABINOIDS FOLLOWING INTRAVENTRICULAR ADMINISTRATION IN RATS [J].
MARTIN, WJ ;
LAI, NK ;
PATRICK, SL ;
TSOU, K ;
WALKER, JM .
BRAIN RESEARCH, 1993, 629 (02) :300-304
[10]   Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception [J].
Mason, DJ ;
Lowe, J ;
Welch, SP .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 378 (03) :237-248